Cardiol Therapeutics (TSE:CRDL) Reaches New 1-Year High at $4.09

Cardiol Therapeutics Inc. (TSE:CRDLGet Free Report)’s share price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as C$4.09 and last traded at C$3.92, with a volume of 202818 shares trading hands. The stock had previously closed at C$3.93.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating on shares of Cardiol Therapeutics in a research report on Monday, April 22nd.

Get Our Latest Stock Report on CRDL

Cardiol Therapeutics Price Performance

The stock has a market cap of C$266.34 million, a price-to-earnings ratio of -8.36 and a beta of 0.68. The company has a 50-day simple moving average of C$2.89 and a two-hundred day simple moving average of C$2.07. The company has a debt-to-equity ratio of 0.83, a quick ratio of 6.84 and a current ratio of 2.81.

Cardiol Therapeutics Company Profile

(Get Free Report)

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Featured Stories

Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.